<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779558</url>
  </required_header>
  <id_info>
    <org_study_id>SU-11132007-879</org_study_id>
    <nct_id>NCT00779558</nct_id>
  </id_info>
  <brief_title>Heparin and the Reduction of Thrombosis (HART) Trial</brief_title>
  <official_title>Heparin and Catheter-related Thrombosis in Neonates and Infants Following Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heparin is frequently used in central venous catheters (CVCs) in post-operative cardiac
      patients. It remains unclear if a heparin infusion, compared to a normal saline infusion,
      prevents thrombosis of CVCs after surgery. This study will answer the question: does a
      low-dose heparin infusion (10 units/kg/h) prevent thrombosis, compared to a normal saline
      infusion, in patients less than one year of age after cardiac surgery?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are contacted pre-operatively and their parents consented. The following criteria
      apply:

      Inclusion criteria:

      All infants &lt; 1 year of age undergoing cardiac surgery at Lucile Packard Children's Hospital

      Exclusion Criteria:

      Known coagulopathy History of clinically significant bleeding (GI, cranial, pulmonary) Need
      for therapeutic heparinization ECMO

      Randomization and blinding are performed in the Pharmacy. The intervention is initiated at
      the intensive care unit physician's discretion, generally within the 1st 24 hours
      post-operatively. The study is terminated when all catheters have been discontinued or at POD
      #14, whichever occurs first.

      Thrombosis is demonstrated by echocardiogram or ultrasound performed at

      1 - 3 days, 5 - 7 days, and 10 - 14 days after initiation of the study drug.

      The following are calculations for statistical analysis:

      Sample size determination - Using 2 - sided alpha = 0.05 and Beta = 0.2, and assuming a
      baseline thrombosis incidence of 20%, 160 patients are required to detect an effect size of
      15%.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombosis</measure>
    <time_frame>While on study drug, which was continued until all catheters were removed, or 2 weeks (whichever came first). Echoes were performed after 24-48 hours and then every 3-5 days</time_frame>
    <description>Echocardiographic evidence of thrombosis while on study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total PRBCs Transfused</measure>
    <time_frame>While on study drug, which was continued until all catheters were removed, or 2 weeks (whichever came first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to Extubation</measure>
    <time_frame>While on study drug, which was continued until all catheters were removed, or 2 weeks (whichever came first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac ICU Length of Stay</measure>
    <time_frame>While on study drug, which was continued until all catheters were removed, or 2 weeks (whichever came first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Antibiotics</measure>
    <time_frame>While on study drug, which was continued until all catheters were removed, or 2 weeks (whichever came first)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>Study drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heparin sulfate infusion at 10 units/kg/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo - normal saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin sulfate infusion at 10 units/kg/hour</intervention_name>
    <description>Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery</description>
    <arm_group_label>Study drug</arm_group_label>
    <other_name>heparin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <description>Infusion of normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All infants &lt; 1 year of age undergoing cardiac surgery at Lucile Packard Children's
             Hospital &amp; #xA

        Exclusion Criteria:

          -  Known coagulopathy

          -  History of clinically significant bleeding (GI, cranial, pulmonary)

          -  Need for therapeutic heparinization

          -  ECMO
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen J. Roth M.D., M.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <results_first_submitted>May 28, 2015</results_first_submitted>
  <results_first_submitted_qc>June 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 12, 2015</results_first_posted>
  <last_update_submitted>June 10, 2015</last_update_submitted>
  <last_update_submitted_qc>June 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Alan Schroeder</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Drug</title>
          <description>Heparin sulfate infusion at 10 units/kg/hour
Heparin sulfate infusion at 10 units/kg/hour: Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo - normal saline infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Drug</title>
          <description>Heparin sulfate infusion at 10 units/kg/hour
Heparin sulfate infusion at 10 units/kg/hour: Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo - normal saline infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="2.7"/>
                    <measurement group_id="B2" value="4.3" spread="3.2"/>
                    <measurement group_id="B3" value="4.2" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Thrombosis</title>
        <description>Echocardiographic evidence of thrombosis while on study drug</description>
        <time_frame>While on study drug, which was continued until all catheters were removed, or 2 weeks (whichever came first). Echoes were performed after 24-48 hours and then every 3-5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug</title>
            <description>Heparin sulfate infusion at 10 units/kg/hour
Heparin sulfate infusion at 10 units/kg/hour: Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - normal saline infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Thrombosis</title>
          <description>Echocardiographic evidence of thrombosis while on study drug</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total PRBCs Transfused</title>
        <time_frame>While on study drug, which was continued until all catheters were removed, or 2 weeks (whichever came first)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug</title>
            <description>Heparin sulfate infusion at 10 units/kg/hour
Heparin sulfate infusion at 10 units/kg/hour: Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - normal saline infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Total PRBCs Transfused</title>
          <units>mL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="13"/>
                    <measurement group_id="O2" value="5.6" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days to Extubation</title>
        <time_frame>While on study drug, which was continued until all catheters were removed, or 2 weeks (whichever came first)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug</title>
            <description>Heparin sulfate infusion at 10 units/kg/hour
Heparin sulfate infusion at 10 units/kg/hour: Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - normal saline infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Days to Extubation</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="3.7"/>
                    <measurement group_id="O2" value="3.3" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac ICU Length of Stay</title>
        <time_frame>While on study drug, which was continued until all catheters were removed, or 2 weeks (whichever came first)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug</title>
            <description>Heparin sulfate infusion at 10 units/kg/hour
Heparin sulfate infusion at 10 units/kg/hour: Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - normal saline infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac ICU Length of Stay</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="9.7"/>
                    <measurement group_id="O2" value="6.9" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Antibiotics</title>
        <time_frame>While on study drug, which was continued until all catheters were removed, or 2 weeks (whichever came first)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug</title>
            <description>Heparin sulfate infusion at 10 units/kg/hour
Heparin sulfate infusion at 10 units/kg/hour: Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - normal saline infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Antibiotics</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Study Drug</title>
          <description>Heparin sulfate infusion at 10 units/kg/hour
Heparin sulfate infusion at 10 units/kg/hour: Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo - normal saline infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alan Schroeder</name_or_title>
      <organization>Stanford University</organization>
      <phone>408 885-5260</phone>
      <email>alan.schroeder@hhs.sccgov.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

